BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology

  Anavex Life Sciences Corp. announced today that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug blarcamesine (ANAVEX ® 2-73) did demonstrate a statistically significant slowing in cognitive decline associated with Alzheimer’s disease.

  September 14, 2023

   · 

  6 min read
• Business

  FluidAI Medical Teams Up with Medtronic for Remote Monitoring via DIGITAL’s Continuous Connected Patient Care Project

  FluidAI Medical, a leading artificial intelligence (AI) startup and developer of the Stream™ Platform for post-surgical monitoring, has announced a strategic partnership with Medtronic Canada ULC, a prominent subsidiary of the global healthcare technology company, Medtronic PLC.

  September 14, 2023

   · 

  7 min read
• Pharm Country

  MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

  Mind Medicine announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually.

  September 14, 2023

   · 

  1 min read
• Business

  Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

  Biophytis SA today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee.

  September 14, 2023

   · 

  4 min read
• Business

  Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

  Landos Biopharma, Inc. today announced a strategic research collaboration to investigate the effects of NX-13 on epithelial cells with the Inflammatory Bowel Disease (IBD) Team at KU Leuven and University Hospitals Leuven (KU Leuven).

  September 14, 2023

   · 

  5 min read
• Lone Star Bio

  Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

  Lumos Pharma, Inc. announced today that an abstract reviewing interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology, to be held in The Hague, Netherlands.

  September 14, 2023

   · 

  2 min read
• Business

  Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer’s Disease

  Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL- Y01 for the treatment of Alzheimer’s disease (AD).

  September 14, 2023

   · 

  2 min read
• Drug Development

  Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

  Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.

  September 14, 2023

   · 

  7 min read
• Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

  Intravacc, a leading Contract Development and Manufacturing Organization specializing in translational research and the development of preventive and therapeutic vaccines, has announced the publication of a review on the efficacy of intranasally administered outer membrane vesicle -based vaccines.

  September 14, 2023

   · 

  3 min read
• Business

  Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland

  Astellas Pharma Inc. announced its intention to submit a planning application to build a new state-of-the-art facility, at an approximate cost of €330 million in Tralee, Co. Kerry.

  September 14, 2023

   · 

  4 min read